NSE: WINDLAS | BSE: 543329

Turnaround Potential

Download real time

863.20 -17.30 (-1.96%)

26,141 NSE+BSE Volume

NSE 22 Jul, 2026 2:11 PM (IST)

1,811.7

Market Cap

Above industry Median

Beta 1Year

Low volatility

Windlas Biotech Ltd. share price target and research reports

Name: Latest research reports of Windlas Biotech Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Windlas Biotech Ltd.
Rating: 3
Author: Prabhudas Lilladhar

Latest analyst research reports with target prices and PDF download for WINDLAS, BSE:543329 Windlas Biotech Ltd.

Search Inside the pdf :

Windlas Biotech Ltd.

05 Aug 2021

863.20

-1.96%

IPO Note - Direct play on CMO offers alternative opportunity for investors - SUBSCRIBE

IPO Note: Windlas Biotech Ltd.

Prabhudas Lilladhar

experience in manufacturing (solid/ liquid) multiple dosage offers a comprehensive range of CDMO services in India. Over time Windlas evolved and 6) strong financial performance with experienced management. It owns...

Windlas Biotech Ltd. is trading above all available SMAs

Windlas Biotech Ltd.

04 Aug 2021

863.20

-1.96%

Windlas Biotech Ltd. IPO Note

IPO Note: Windlas Biotech Ltd.

Ashika Research

5 each, (Comprising of fresh issue of 3,586,957 Equity Shares* (Rs. 165 cr.) and Offer for Sale of 5,142,067 Equity Shares (Rs. 236.5 cr.*) by Selling Shareholder)....

Windlas Biotech Ltd. is trading above all available SMAs

Windlas Biotech Ltd.

03 Aug 2021

863.20

-1.96%

Windlas Biotech Limited

IPO Subscribe: Windlas Biotech Ltd.

Angel Broking

Windlas Biotech Ltd. The company was incorporated in 2001 based in Dehradun. The Company operating with 3 business verticals 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market 3. Exports. The company currently owns and operates four manufacturing facilities located at Dehradun in Uttarakhand. As of March 31, 2021, their

Number of FII/FPI investors increased from 39 to 48 in Jun 2026 qtr.

Windlas Biotech Ltd.

03 Aug 2021

863.20

-1.96%

Windlas Biotech Ltd : IPO

IPO Note: Windlas Biotech Ltd.

ICICI Securities Limited

Leading player in fast growing CDMO market With increasing globalisation and focus of large pharmaceutical players on cutting costs and optimising operations, CDMOs have seen significant acceptance in the pharmaceutical industry internationally over the last few years. The domestic formulations CDMO market has grown at a higher rate of ~13% compared to ~8.6% growth of the domestic formulations market (in terms of consumption) in the past five years. The company believe this increasing use of outsourcing by pharmaceutical companies for launch of...

Number of FII/FPI investors increased from 39 to 48 in Jun 2026 qtr.

VOTE: Is Windlas Biotech Ltd. worth buying?

71 Votes:

Buy 85.92%

Sell 11.27%

Hold 2.82%